Castagnola Elio, Bagnasco Francesca, Amoroso Loredana, Caviglia Ilaria, Caruso Silvia, Faraci Maura, Calvillo Michaela, Moroni Cristina, Bandettini Roberto, Cangemi Giuliana, Magnano Gian Michele, Buffa Piero, Moscatelli Andrea, Haupt Riccardo
From the *Infectious Diseases Unit; †Epidemiology and Biostatistics Unit; ‡Oncology Unit; §Hemopoietic Stem Cell Transplant Unit; ¶Hematology Unit; ‖Laboratory of Analysis; **Service of Radiology; ††Surgery Unit; and ‡‡Intensive Care Unit, "Istituto Giannina Gaslini", Genova, Italy.
Pediatr Infect Dis J. 2014 Mar;33(3):233-7. doi: 10.1097/INF.0000000000000101.
In the last decades, several diagnostic and therapeutic strategies have been implemented for management of invasive fungal diseases (IFD) in patients with cancer or receiving allogeneic hemopoietic stem cell transplant. Few data are available on their impact on mortality in children.
All IFD episodes diagnosed at tertiary care center during a 30-year period between 1983 and 2012 were analyzed for 90-day mortality and risk factors. Diagnoses were coded according to international (European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group) criteria. Four treatment eras (1983-1990, 1991-1999, 2000-2005 and 2006-2012) were defined according to availability of diagnostic technologies, new antifungal drugs and use of a diagnostic-driven approach without empiric antifungal therapy.
A total of 198 IFD were diagnosed in 191 patients; 71.2% were proven/probable infections; 39.9% were caused by yeasts and 31.3% by molds. Within 90 days from IFD diagnosis, 58 (30.4%) patients died for a 28.3% cumulative probability of death. A multivariable analysis showed that the highest risk of death was associated with alternative donor-hemopoietic stem cell transplant [hazard ratio (HR): 3.96] and mold etiology (HR: 1.34). The risk of death significantly decreased across the treatment eras, with almost a 3-fold reduced risk for patients diagnosed during the 2006-2012 period (HR: 0.24). Also if the variable year of diagnosis was considered as continuous, the hazard of death significantly decreased by 5% per year (HR: 0.95).
New management strategies resulted in a better prognosis of IFD in children with cancer or hemopoietic stem cell transplant. A diagnostic-driven approach was not associated with an increase in mortality.
在过去几十年中,已实施了多种诊断和治疗策略来管理癌症患者或接受异基因造血干细胞移植患者的侵袭性真菌病(IFD)。关于这些策略对儿童死亡率影响的数据很少。
分析了1983年至2012年期间在三级医疗中心诊断出的所有IFD病例的90天死亡率及危险因素。诊断按照国际(欧洲癌症研究与治疗组织/侵袭性真菌感染合作组以及美国国立过敏与传染病研究所真菌病研究组)标准进行编码。根据诊断技术的可用性、新型抗真菌药物以及采用无经验性抗真菌治疗的诊断驱动方法,定义了四个治疗时代(1983 - 1990年、1991 - 1999年、2000 - 2005年和2006 - 2012年)。
共在191例患者中诊断出198例IFD;71.2%为确诊/疑似感染;39.9%由酵母菌引起,31.3%由霉菌引起。在IFD诊断后的90天内,58例(30.4%)患者死亡,累积死亡概率为28.3%。多变量分析显示,死亡风险最高与替代供体造血干细胞移植相关[风险比(HR):3.96]以及霉菌病因(HR:1.34)。在各个治疗时代,死亡风险显著降低,2006 - 2012年期间诊断出的患者风险降低了近3倍(HR:0.24)。即使将诊断年份变量视为连续变量,死亡风险每年也显著降低5%(HR:0.95)。
新管理策略使癌症或造血干细胞移植儿童的IFD预后更好。诊断驱动方法与死亡率增加无关。